GSK oncology chief jumps to biotech partner Adaptimmune; ArGEN-X adds checkpoint program to pipeline;

@FierceBiotech: Scripps investigators ID a key player in disarming chemotherapy. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: Bristol-Myers forges a billion-dollar cancer vaccine deal with Bavarian Nordic. News | Follow @JohnCFierce

@DamianFierce: Alkahest, a @JNJInnovation incuabatee, signed a $50M deal with Grifols. Release | Follow @DamianFierce

> As head of oncology R&D at GlaxoSmithKline ($GSK), Rafael Amado became a passionate supporter of Adaptimmune's R&D strategy for TCRs, genetically reengineering T cells to attack cancer in a field closely related to CAR-Ts. Amado played a lead role in establishing a major, $350 million-plus partnership with the U.K. biotech last year. Now, with GSK completing its deal to flip its cancer drug portfolio to Novartis ($NVS), Amado has jumped to the biotech as its new chief medical officer. Adrian Rawcliffe has joined Adaptimmune as CFO. Release (PDF)

> Belgium's arGEN-X says it has inlicensed a preclinical checkpoint inhibitor and added it to the pipeline. ARGX-115 targets GARP, a novel checkpoint target. Release

> Australian penny stock company Novogen ($NVGN) got a boost after it touted a recent study that may have demonstrated that its lead drug demonstrated some potential in fighting brain cancer. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Nevro appoints former JJDC head to board as it awaits anticipated FDA approval. Article | Follow @FierceMedDev

@VarunSaxena2: FDA requires new labeling on insulin pens to ward off spread of infections. More from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: Pharma CMO? Meet your CIO--and start working together already. FiercePharmaMarketing article | Follow @EmilyWFierce

> Studies show need to supplement mammography with MRI, ultrasound for dense breast tissue. News

> Intuitive Surgical returns to the battlefield with $430M DOD contract. Article

> S&N falls on Stryker buyback plan, buys into Latin American distributor. Story

Pharma News

@FiercePharma: Pfizer shuttering vitamin C plant in California, 70 workers out of jobs. FiercePharmaManufacturing story | Follow @FiercePharma

@EricPFierce: UK starts on $85M cell manufacturing facility as report shows country has become net importer of drugs. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Merck's Rebif held its own in last year's MS market shakeup. What about 2015? More | Follow @CarlyHFierce

> FDA calls for heart, stroke warnings on 'Low T' meds. Report

> Takeda's Weber must execute now that he is CEO. Article

Drug Delivery News

> Chrono Therapeutics ropes in new funds from Rock Health for smoking cessation device. Story

> Forbes gives drug delivery a shoutout, says it can make good drugs great. Item

> FDA requires new labeling on insulin pens to ward off spread of infections. Article

> Amgen launches delivery device for automatic administration of its blockbuster Neulasta. News

> Evidence that inhaled oxytocin improves social behavior among autistic patients spurs R&D. More

Diagnostics News

> FDA grants emergency use authorization to Corgenix's fast acting Ebola diagnostic. Article

> RainDance waltzes toward $60M IPO. News

> Skin test could vastly simplify diagnosis of Alzheimer's and Parkinson's. More

> Exact Sciences beefs up sales and reimbursement efforts for colon cancer Dx. Story

> Vigilant Biosciences reels in $5.5M for oral cancer test. Report

Pharma Marketing News

> The long, strange story of Cubist's Cards Against Biotechnology. Feature

> Goldman cuts Afrezza sales forecast in half on slow uptake, pricing pressure. Report

> Surprise: Obesity med Contrave might help CV outcomes. Too bad Orexigen blabbed it. More

> The PD-1 wave? Report says it's a $33B tsunami, with BMS surfing for first place. Story

> Pharma CMO? Meet your CIO--and start working together already. Article

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.